| STK11/LKB1 Mutations and PD-1 Inhibitor Resistance in KRAS-Mutant Lung Adenocarcinoma F Skoulidis, ME Goldberg, DM Greenawalt, MD Hellmann, MM Awad, ... Cancer discovery 8 (7), 822-835, 2018 | 1359 | 2018 |
| Co-occurring Genomic Alterations Define Major Subsets of KRAS-Mutant Lung Adenocarcinoma with Distinct Biology, Immune Profiles, and Therapeutic … F Skoulidis, LA Byers, L Diao, VA Papadimitrakopoulou, P Tong, J Izzo, ... Cancer discovery 5 (8), 860-877, 2015 | 844 | 2015 |
| Neoadjuvant chemotherapy and nivolumab in resectable non-small-cell lung cancer (NADIM): an open-label, multicentre, single-arm, phase 2 trial M Provencio, E Nadal, A Insa, MR García-Campelo, J Casal-Rubio, ... The Lancet Oncology 21 (11), 1413-1422, 2020 | 712 | 2020 |
| Fecal microbiota transplantation for refractory immune checkpoint inhibitor-associated colitis Y Wang, DH Wiesnoski, BA Helmink, V Gopalakrishnan, K Choi, ... Nature medicine 24 (12), 1804-1808, 2018 | 642 | 2018 |
| Neoadjuvant nivolumab or nivolumab plus ipilimumab in operable non-small cell lung cancer: the phase 2 randomized NEOSTAR trial T Cascone, WN William Jr, A Weissferdt, CH Leung, HY Lin, A Pataer, ... Nature medicine 27 (3), 504-514, 2021 | 512 | 2021 |
| A patient-derived, pan-cancer EMT signature identifies global molecular alterations and immune target enrichment following epithelial-to-mesenchymal transition MP Mak, P Tong, L Diao, RJ Cardnell, DL Gibbons, WN William, ... Clinical Cancer Research 22 (3), 609-620, 2016 | 449 | 2016 |
| Validation of multiplex immunofluorescence panels using multispectral microscopy for immune-profiling of formalin-fixed and paraffin-embedded human tumor tissues ER Parra, N Uraoka, M Jiang, P Cook, D Gibbons, MA Forget, ... Scientific reports 7 (1), 13380, 2017 | 272 | 2017 |
| A proteogenomic portrait of lung squamous cell carcinoma S Satpathy, K Krug, PMJ Beltran, SR Savage, F Petralia, C Kumar-Sinha, ... Cell 184 (16), 4348-4371. e40, 2021 | 246 | 2021 |
| Association of interferon‐and transforming growth factor β–regulated genes and macrophage activation with systemic sclerosis–related progressive lung fibrosis RB Christmann, P Sampaio‐Barros, G Stifano, CL Borges, ... Arthritis & rheumatology 66 (3), 714-725, 2014 | 229 | 2014 |
| The Society for Immunotherapy in Cancer statement on best practices for multiplex immunohistochemistry (IHC) and immunofluorescence (IF) staining and validation JM Taube, G Akturk, M Angelo, EL Engle, S Gnjatic, S Greenbaum, ... Journal for immunotherapy of cancer 8 (1), 2020 | 222 | 2020 |
| Whole-exome sequencing and immune profiling of early-stage lung adenocarcinoma with fully annotated clinical follow-up H Kadara, M Choi, J Zhang, ER Parra, J Rodriguez-Canales, SG Gaffney, ... Annals of Oncology 28 (1), 75-82, 2017 | 201 | 2017 |
| Comprehensive T cell repertoire characterization of non-small cell lung cancer A Reuben, J Zhang, SH Chiou, RM Gittelman, J Li, WC Lee, J Fujimoto, ... Nature communications 11 (1), 603, 2020 | 194 | 2020 |
| TCR repertoire intratumor heterogeneity in localized lung adenocarcinomas: an association with predicted neoantigen heterogeneity and postsurgical recurrence A Reuben, R Gittelman, J Gao, J Zhang, EC Yusko, CJ Wu, R Emerson, ... Cancer discovery 7 (10), 1088-1097, 2017 | 191 | 2017 |
| Comparison of different antibody clones for immunohistochemistry detection of programmed cell death ligand 1 (PD-L1) on non–small cell lung carcinoma ER Parra, P Villalobos, B Mino, J Rodriguez-Canales Applied Immunohistochemistry & Molecular Morphology 26 (2), 83-93, 2018 | 165 | 2018 |
| Correlative analyses of the SARC028 trial reveal an association between sarcoma-associated immune infiltrate and response to pembrolizumab EZ Keung, M Burgess, R Salazar, ER Parra, J Rodrigues-Canales, ... Clinical Cancer Research 26 (6), 1258-1266, 2020 | 156 | 2020 |
| Image analysis–based assessment of PD-L1 and tumor-associated immune cells density supports distinct intratumoral microenvironment groups in non–small cell lung carcinoma patients ER Parra, C Behrens, J Rodriguez-Canales, H Lin, B Mino, J Blando, ... Clinical Cancer Research 22 (24), 6278-6289, 2016 | 153 | 2016 |
| Co-occurring genomic alterations define major subsets of KRAS-mutant lung adenocarcinoma with distinct biology, immune profiles, and therapeutic vulnerabilities. Cancer Discov … F Skoulidis, LA Byers, L Diao, VA Papadimitrakopoulou, P Tong, J Izzo, ... DOI: https://doi. org/10.1158/2159-8290. CD-14-1236, 860-877, 2012 | 152 | 2012 |
| Effect of neoadjuvant chemotherapy on the immune microenvironment in non–small cell lung carcinomas as determined by multiplex immunofluorescence and image analysis approaches ER Parra, P Villalobos, C Behrens, M Jiang, A Pataer, SG Swisher, ... Journal for immunotherapy of cancer 6, 1-11, 2018 | 151 | 2018 |
| Development of an immune-pathology informed radiomics model for non-small cell lung cancer C Tang, B Hobbs, A Amer, X Li, C Behrens, JR Canales, EP Cuentas, ... Scientific reports 8 (1), 1922, 2018 | 146 | 2018 |
| Multiplatform-based molecular subtypes of non-small-cell lung cancer F Chen, Y Zhang, E Parra, J Rodriguez, C Behrens, R Akbani, Y Lu, ... Oncogene 36 (10), 1384-1393, 2017 | 127 | 2017 |
